STOCK TITAN

Cosmos Holdings (COSM) Stock News

COSM NASDAQ

Cosmos Health Inc. reports developments across a vertically integrated healthcare platform that includes wholesale pharmaceutical distribution, contract manufacturing, proprietary nutraceutical brands and research and development. Recurring updates cover U.S. commercialization of the 18 Series nutraceutical portfolio, including Noor18, Liv18, Cur18 and Fort18, as well as Sky Premium Life orders, international distribution relationships and product launches.

Company news also covers financial results, margin and revenue drivers at Cana Laboratories, CosmoFarm and Decahedron, AI investments including the Cloudscreen drug-repurposing platform, and Nasdaq listing-compliance or governance matters tied to its common stock.

Rhea-AI Summary

Cosmos Health (COSM) intends to resume open-market share repurchases, and its executive officers and directors have agreed to a 12-month lock-up.

Approximately $3.85 million remains available under the $5.0 million buyback program the board authorized on June 26, 2026. Cosmos Health has repurchased 255,600 shares (5,112,000 pre-split) for approximately $1.15 million. Future purchases depend on market conditions and other factors. The lock-up bars the officers and directors from selling or otherwise disposing of any common shares they hold.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.71%
Tags
buybacks
-
Rhea-AI Summary

Cosmos Health (COSM) reported record revenue of $53.6 million for the first nine months of 2026. Revenue rose 17.6% year over year, but the nine-month net loss widened to $14.15 million from $9.00 million. Q3 revenue fell to $16.68 million from $17.11 million a year earlier. Q3 gross margin rose 465 basis points from Q2 to 12.6%, and Q3 net loss narrowed to $5.25 million from $5.35 million a year earlier.

Since year-end 2025, total debt fell 33.8% to $12.83 million and stockholders’ equity rose 21.2% to $22.33 million. Cosmos Health fully settled its $8.0 million ATW convertible note. Cana Laboratories’ contract manufacturing pipeline rose 31% since June to more than 32.7 million units. Cosmos Health completed a 1-for-20 reverse stock split effective November 13, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.51%
Tags
-
Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) reported U.S. monthly subscription value of $1,832,785 as of October 31, 2026, for its direct-to-consumer business. This is equivalent to approximately $22.0 million annualized, rather than reported annual sales. October U.S. e-commerce sales totaled $1,673,004, including $1,015,231 attributable to subscriptions.

Active subscriptions reached 12,532, with net growth of 11,544 during October. They covered 29,507 product units, approximately 2.4 per subscription. October recorded approximately 19,100 orders from approximately 234,500 store sessions, with a reported conversion rate of 7.72%. Cosmos Health increased its marketing budget for fourth-quarter expansion and plans to expand digital customer acquisition, grow subscriptions and add portfolio products to its U.S. online stores. The company said U.S. e-commerce sales continued growing into November.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.36%
Tags
none
Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) has begun commissioning automated order-processing and vehicle-loading infrastructure at its CosmoFarm subsidiary’s distribution center in Peristeri, Athens. Engineers are configuring and testing the order-processing equipment; loading lanes have been installed.

CosmoFarm reached an annualized revenue run-rate of over $60 million based on second-quarter 2026 revenue, more than four times its pre-acquisition revenue, with momentum continuing into the third quarter. Cosmos Health believes ongoing automation investments could support over $120 million in annual revenue and expects faster handling to allow more pharmacies on existing routes at limited incremental cost.

A further network acquisition remains at the letter of intent stage. The target generates approximately €10 million (approximately $11.3 million) in annual gross revenue. Completion requires a definitive agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.51%
Tags
none
-
Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) reported Amazon UK sales growth of 90% for its trailing twelve-month period, alongside profitable channel operations. Sales reached £1.71 million, or approximately $2.27 million, versus approximately $1.19 million in the prior period. The reported period ran from November 1, 2025 to November 2, 2026, with 116,978 units sold.

After direct channel costs, Amazon UK generated net profit of approximately $525,000, with an approximately 23% net margin. Advertising represented 2.4% of sales, and refunds remained below 1%. Monthly sales rose from approximately $144,000 in November 2025 to more than $215,000 in each month from July through October 2026. Cosmos Health expects sales over the next twelve months to grow approximately 72% to approximately $3.9 million, based on current sales trends and planned platform growth initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.73%
Tags
none
-
Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) reported 12,050 active U.S. subscriptions as of October 28, 2026, reflecting growth in its direct-to-consumer business.

Subscriptions rose 92% in two weeks from 6,287 on October 14 and 35% from 8,940 nine days earlier. Monthly subscription value increased 94% over two weeks, from $919,945 to $1,787,585. This metric represents what active subscriptions would bill monthly at standard renewal pricing, rather than reported revenue. Platform-tracked online checkout orders reached 20,677, up 41% from October 19 and 90% from October 14.

The U.S. subscription model launched in mid-July, with scaling beginning in mid-September alongside accelerated platform investment. Cosmos Health expects the recurring portion of U.S. revenue to grow as monthly subscriber groups renew. The same model is now live in Australia, New Zealand and the broader Oceania region.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.45%
Tags
none
Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) announced Noble Capital Markets initiated company-sponsored research coverage with an Outperform rating and a $1.40 price target. The target is approximately 493% above the October 27, 2026 closing price of $0.236.

Noble forecasts revenue of $90.0 million in 2026, up approximately 38%, followed by $131.2 million in 2027 and $160.8 million in 2028; adjusted EBITDA, an adjusted earnings measure, turning positive at $3.9 million in 2026 and reaching $27.4 million in 2028; and gross margin rising from 12.1% in 2025 to 31.5% in 2028. Its fourth-quarter 2026 estimates are $35.7 million in revenue, $6.4 million in adjusted EBITDA and 40.1% gross margin. Free cash flow is forecast to turn positive at $10.0 million in 2027 and reach $16.8 million in 2028. These are analyst estimates, not reported results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.51%
Tags
none
-
Rhea-AI Summary

Cosmos Health (COSM) has launched its e-commerce and subscription business in Australia, New Zealand and broader Oceania, with sales already underway. Customers can buy products through the company's online stores and choose recurring delivery at checkout.

The expansion follows a U.S. direct-to-consumer business that had 8,940 active subscriptions and 14,624 online checkout orders as of October 19, 2026. Cosmos Health intends to continue evaluating additional international markets for its direct-to-consumer subscription model as it builds a global recurring customer base.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.87%
Tags
none
-
Rhea-AI Summary

Cosmos Health (COSM) reported preliminary nine-month revenue of approximately $54.3 million and reaffirmed its expectation for record full-year revenue. Revenue rose 19% year over year; the company expects 2026 revenue to surpass $90 million, implying fourth-quarter revenue of approximately $35.7 million or more.

Its U.S. business had 8,940 active subscriptions as of October 19. Cosmos expects approximately $15 million in fourth-quarter U.S. revenue at an approximately 70% gross margin, supported by a significantly expanded marketing budget. Cana's contract manufacturing pipeline exceeds 32.7 million units, with more than $20 million in implied revenue over the agreements' lives, subject to execution. Total liabilities fell 13.3% between December 2025 and June 2026. Cosmos targets a 35.5% gross margin by fiscal 2029, versus 12.1% in fiscal 2025, and has a non-binding acquisition letter of intent for a Greek pharmacy distribution network.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
none
Rhea-AI Summary

Cosmos Health (COSM) expects approximately $15 million in U.S. revenue for the fourth quarter of 2026 from its online direct-to-consumer business. The company forecasts approximately $10.5 million in gross profit at an approximately 70% gross margin, supported by an expanded marketing budget.

Expected revenue comprises approximately $8.2 million from new subscribers' first orders, $3.3 million from renewals of subscriptions started during the quarter and $3.5 million from one-time purchases. Active U.S. subscriptions reached 8,940 on October 19, up 42% from 6,287 on October 14; platform subscription and order figures are preliminary and unaudited. Cosmos Health expects daily U.S. sales to rise from $60,000 at the quarter's start to more than $200,000 by year-end, with active U.S. subscriptions exceeding 40,000 by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.90%
Tags

FAQ

What is the current stock price of Cosmos Holdings (COSM)?

Cosmos Holdings (COSM) last closed at $2.81.

What is the market cap of Cosmos Holdings (COSM)?

The market cap of Cosmos Holdings (COSM) is approximately $14.1M.